JP7762957B2 - Ｍｅｔｔｌ３阻害化合物 - Google Patents

Ｍｅｔｔｌ３阻害化合物

Info

Publication number
JP7762957B2
JP7762957B2 JP2021560410A JP2021560410A JP7762957B2 JP 7762957 B2 JP7762957 B2 JP 7762957B2 JP 2021560410 A JP2021560410 A JP 2021560410A JP 2021560410 A JP2021560410 A JP 2021560410A JP 7762957 B2 JP7762957 B2 JP 7762957B2
Authority
JP
Japan
Prior art keywords
methyl
pyridin
imidazo
carboxamide
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021560410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022528562A5 (https=
JP2022528562A (ja
Inventor
ピーター ブラッカビー，ウェズリー
ジェイムズ ハーディック，デイビッド
ジェーン トーマス，エリザベス
アーサー ブルックフィールド，フレデリック
ブバート，クリスティアン
シェパード，ジョン
ピーター リドギル，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Storm Therapeutics Ltd
Original Assignee
Storm Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1904848.7A external-priority patent/GB201904848D0/en
Priority claimed from GBGB1912603.6A external-priority patent/GB201912603D0/en
Priority claimed from GBGB1919095.8A external-priority patent/GB201919095D0/en
Application filed by Storm Therapeutics Ltd filed Critical Storm Therapeutics Ltd
Publication of JP2022528562A publication Critical patent/JP2022528562A/ja
Publication of JP2022528562A5 publication Critical patent/JP2022528562A5/ja
Application granted granted Critical
Publication of JP7762957B2 publication Critical patent/JP7762957B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021560410A 2019-04-05 2020-04-03 Ｍｅｔｔｌ３阻害化合物 Active JP7762957B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1904848.7 2019-04-05
GBGB1904848.7A GB201904848D0 (en) 2019-04-05 2019-04-05 Inhibitory compounds
GB1912603.6 2019-09-02
GBGB1912603.6A GB201912603D0 (en) 2019-09-02 2019-09-02 Inhibitory compounds
GB1919095.8 2019-12-20
GBGB1919095.8A GB201919095D0 (en) 2019-12-20 2019-12-20 Inhibitory compounds
PCT/GB2020/050898 WO2020201773A1 (en) 2019-04-05 2020-04-03 Mettl3 inhibitory compounds

Publications (3)

Publication Number Publication Date
JP2022528562A JP2022528562A (ja) 2022-06-14
JP2022528562A5 JP2022528562A5 (https=) 2023-04-10
JP7762957B2 true JP7762957B2 (ja) 2025-10-31

Family

ID=70285722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560410A Active JP7762957B2 (ja) 2019-04-05 2020-04-03 Ｍｅｔｔｌ３阻害化合物

Country Status (5)

Country Link
US (2) US12358915B2 (https=)
EP (1) EP3946618A1 (https=)
JP (1) JP7762957B2 (https=)
CN (1) CN113905787A (https=)
WO (1) WO2020201773A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物
WO2022074379A1 (en) * 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
US11944608B2 (en) * 2020-10-26 2024-04-02 New York University Targeting RNA viruses using inhibitors of METTL3
CA3219183A1 (en) * 2021-05-17 2022-11-24 Amedeo Caflisch N6-adenosine-methyltransferase inhibitors in cancer treatment
GB202107905D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Processes for the preparation of inhibitory compounds
GB202107907D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
CN116514805A (zh) * 2021-12-10 2023-08-01 成都先导药物开发股份有限公司 Mettl3抑制剂化合物
CN118660890A (zh) * 2022-02-11 2024-09-17 西藏海思科制药有限公司 一种mettl3抑制剂及组合物及其在医药上的应用
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途
CN114869891A (zh) * 2022-04-28 2022-08-09 复旦大学附属中山医院 Mettl3抑制剂在制备治疗肝癌药物中的应用
CN117045801A (zh) * 2022-05-13 2023-11-14 中国科学院广州生物医药与健康研究院 m6A RNA甲基化酶抑制剂与免疫检查点抑制剂联合治疗肿瘤
CN117720533A (zh) * 2022-09-16 2024-03-19 北京华益健康药物研究中心 Mettl3抑制剂化合物及其药物组合物和应用
WO2024107763A1 (en) * 2022-11-16 2024-05-23 University Of Zurich N6-adenosine-methyltransferase protacs and methods of use thereof
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
CN120731203A (zh) 2023-01-20 2025-09-30 艾匹克治疗公司 作为mettl3抑制剂的哌啶衍生物
AU2024244637A1 (en) 2023-03-30 2025-10-16 Aqemia Novel mettl3 inhibitors and use thereof in therapy
GB202316683D0 (en) * 2023-10-31 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
WO2025237957A1 (en) 2024-05-14 2025-11-20 Institut Curie Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor
WO2026067558A1 (zh) * 2024-09-25 2026-04-02 中国科学院上海药物研究所 稠合双环类化合物及其制备方法、组合物和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506387A (ja) 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド カリウムチャンネルオープナーとしてのベンズアニリド
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
JP2005509003A (ja) 2001-11-09 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼインヒビターとして有用なベンゾイミダゾール化合物
WO2008016131A1 (en) 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP2009530233A (ja) 2006-02-14 2009-08-27 ノバルティス アーゲー Ｐｉ−３キナーゼインヒビターおよびそれらの使用方法
JP2010527909A (ja) 2007-06-05 2010-08-19 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
JP2011509250A (ja) 2008-01-02 2011-03-24 サノフイ−アベンテイス Ｎ−複素環式イミダゾ［１，２−ａ］ピリジン−２−カルボキサミドの誘導体、この調製およびこの治療的用途
WO2018169994A1 (en) 2017-03-13 2018-09-20 City Of Hope m6A mRNA MODIFICATION IN CANCER TREATMENT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3946031A (en) 1973-10-04 1976-03-23 Syntex Inc. 2-Substituted-1,2,4-thiadiazolo-[2,3-a]-benzimidazoles
US3880874A (en) * 1973-10-04 1975-04-29 Syntex Inc 2-Substituted -1,2,4-thiadiazolo-(2,3-a)benzimidazoles and process for their preparation
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
CA2793086C (en) 2010-03-18 2018-08-21 Institut Pasteur Korea Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
CN115151540A (zh) * 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506387A (ja) 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド カリウムチャンネルオープナーとしてのベンズアニリド
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
JP2005509003A (ja) 2001-11-09 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼインヒビターとして有用なベンゾイミダゾール化合物
JP2009530233A (ja) 2006-02-14 2009-08-27 ノバルティス アーゲー Ｐｉ−３キナーゼインヒビターおよびそれらの使用方法
WO2008016131A1 (en) 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP2010527909A (ja) 2007-06-05 2010-08-19 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
JP2011509250A (ja) 2008-01-02 2011-03-24 サノフイ−アベンテイス Ｎ−複素環式イミダゾ［１，２−ａ］ピリジン−２−カルボキサミドの誘導体、この調製およびこの治療的用途
WO2018169994A1 (en) 2017-03-13 2018-09-20 City Of Hope m6A mRNA MODIFICATION IN CANCER TREATMENT

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Herath, Ananda et al.，Continuous-flow synthesis of highly functionalized imidazo-oxadiazoles facilitated by microfluidic extraction，Beilstein Journal of Organic Chemistry ，2017年，13，239-246
REGISTRY（STN）[online]，2018.03.02 [検索日 2024.02.20]CAS登録番号 2183120-12-7 ほか８件
Ukhin, L.Y. et al.，Synthesis of phthalimidines linked to quinoline derivatives by an amide bridge，Russian Chemical Bulletin，2010年，59，1023-1030

Also Published As

Publication number Publication date
WO2020201773A1 (en) 2020-10-08
US12358915B2 (en) 2025-07-15
US20250388577A1 (en) 2025-12-25
CN113905787A (zh) 2022-01-07
EP3946618A1 (en) 2022-02-09
US20230085408A1 (en) 2023-03-16
JP2022528562A (ja) 2022-06-14

Similar Documents

Publication Publication Date Title
JP7762957B2 (ja) Ｍｅｔｔｌ３阻害化合物
JP7765088B2 (ja) Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物
JP7534379B2 (ja) ベンズイミダゾロン由来のｂｃｌ６阻害剤
EP3630749B9 (en) 2-quinolone derived inhibitors of bcl6
CN106459035B (zh) N2‑苯基‑吡啶并[3,4‑d]嘧啶‑2,8‑二胺衍生物及其作为mps1抑制剂的用途
EP2892890A1 (en) Pharmacologically active compounds
WO2022074379A1 (en) Mettl3 inhibitory compounds
WO2024020419A1 (en) Aza-quinazoline compounds and methods of use
JP2026500923A (ja) 阻害性化合物
RU2858287C2 (ru) Полигетероциклические соединения в качестве ингибиторов mettl3
HK40111504A (en) Benzimidazolone derived inhibitors of bcl6
BR112019024830B1 (pt) Inibidores de bcl6 derivados de benzimidazolona, seus usos e composição farmacêutica
HK40025715B (en) Benzimidazolone derived inhibitors of bcl6
HK40025715A (en) Benzimidazolone derived inhibitors of bcl6

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230331

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251014

R150 Certificate of patent or registration of utility model

Ref document number: 7762957

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150